[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J].Hepatology, 2012, 55 (6) :2005-2023.
|
[2]MUSSO G, CASSADER M, ROSINA F, et al.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) :a systematic review and meta-analysis of randomised trials[J].Diabetologia, 2012, 55 (4) :885-904.
|
[3]WONG VW, CHAN RS, WONG GL, et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:A randomized controlled trial[J].J Hepatol, 2013, 59 (3) :536-542.
|
[4]CENTIS E, MOSCATIELLO S, BUGIANESI E, et al.Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease[J].J Hepatol, 2013, 58 (4) :771-777.
|
[5]KEATING SE, HACKETT DA, GEORGE J, et al.Exercise and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 57 (1) :157-166.
|
[6]SULLIVAN S, KIRK EP, MITTENDORFER B, et al.Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (6) :1738-1745.
|
[7]NASCIMBENI F, PAIS R, BELLENTANI S, et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol, 2013, 59 (4) :859-871.
|
[8]STEPHEN S, BARANOVA A, YOUNOSSI ZM.Nonalcoholic fatty liver disease and bariatric surgery[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (2) :163-171.
|
[9]VERDAM FJ, SCHOUTEN R, GREVE JW, et al.An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery[J].J Obes, 2012, 2012:597871.
|
[10]BELL LN, WANG J, MURALIDHARAN S, et al.Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis:a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study[J].Hepatology, 2012, 56 (4) :1311-1318.
|
[11]HOOFNAGLE JH, van NATTA ML, KLEINER DE, et al.Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2013, 38 (2) :134-143.
|
[12]D'ADAMO E, MARCOVECCHIO ML, GIANNINI C, et al.Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E[J].Free Radic Res, 2013, 47 (3) :146-153.
|
[13]MUDALIAR S, HENRY RR, SANYAL AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type2 diabetes and nonalcoholic fatty liver disease[J].Gastroenterology, 2013, 145 (3) :574-582.e1.
|
[14]ADORINI L, PRUZANSKI M, SHAPIRO D.Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis[J].Drug Discov Today, 2012, 17 (17-18) :988-997.
|
[15]KRAJMALNIK-BROWN R, ILHAN ZE, KANG DW, et al.Effects of gut microbes on nutrient absorption and energy regulation[J].Nutr Clin Pract, 2012, 27 (2) :201-214.
|
[16]PARNELL JA, RAMAN M, RIOUX KP, et al.The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance[J].Liver Int, 2012, 32 (5) :701-711.
|
[17]ENDO H, NIIOKA M, KOBAYASHI N, et al.Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats:new insight into the probiotics for the gut-liver axis[J].PLoS One, 2013, 8 (5) :e63388.
|
[18]ST-JULES DE, WATTERS CA, BRUNT EM, et al.Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2013, Jun 30.[Epub ahead of print]
|
[19]TANAKA N, SANO K, HORIUCHI A, et al.Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2008, 42 (4) :413-418.
|
[20]CAPANNI M, CALELLA F, BIAGINI MR, et al.Prolonged n-3polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a pilot study[J].Aliment Pharmacol Ther, 2006, 23 (8) :1143-1151.
|
[21]PARKER HM, JOHNSON NA, BURDON CA, et al.Omega-3supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 56 (4) :944-951.
|
[22]SCORLETTI E, BYRNE CD.Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease[J].Annu Rev Nutr, 2013, 33:231-248.
|
[23]LPEZ-VICARIO C, GONZLEZ-PERIZ A, RIUS B, et al.Molecular interplay between Delta5/Delta6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis[J].Gut, 2013, Mar 14.[Epub ahead of print]
|
[24]SAMSON SL, BAJAJ M.Potential of incretin-based therapies for non-alcoholic fatty liver disease[J].J Diabetes Complications, 2013, 27 (4) :401-406.
|
[25]ZEIN CO, YERIAN LM, GOGATE P, et al.Pentoxifylline improves nonalcoholic steatohepatitis:a randomized placebo-controlled trial[J].Hepatology, 2011, 54 (5) :1610-1619.
|
[26]SHARGORODSKY M, OMELCHENKO E, MATAS Z, et al.Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis:effects beyond glucose lowering?[J].Cardiovasc Diabetol, 2012, 11:61.
|
[27]CHEN HP, SHIEH JJ, CHANG CC, et al.Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner:population-based and in vitro studies[J].Gut, 2013, 62 (4) :606-615.
|
[28]NSEIR W, MOGRABI J, GHALI M.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis:human studies[J].Dig Dis Sci, 2012, 57 (7) :1773-1781.
|
[29]HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al.Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:a randomized controlled pilot study[J].Hepat Mon, 2012, 12 (8) :e6099.
|
[30]LOGUERCIO C, ANDREONE P, BRISC C, et al.Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease:a randomized controlled trial[J].Free Radic Biol Med, 2012, 52 (9) :1658-1665.
|
[31]SHI KQ, FAN YC, LIU WY, et al.Traditional Chinese medicines benefit to nonalcoholic fatty liver disease:a systematic review and meta-analysis[J].Mol Biol Rep, 2012, 39 (10) :9715-9722.
|
[1] | Huang YingTing, Dai Biao. Association between fatty liver disease and lacunar infarction[J]. Journal of Clinical Hepatology, 2018, 34(12): 2619-2623. doi: 10.3969/j.issn.1001-5256.2018.12.022 |
[2] | Gao Fan, Qi XingShun, Hou Yue, Guo XiaoZhong. Association between pancreatitis and fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(1): 40-45. doi: 10.3969/j.issn.1001-5256.2017.01.008 |
[3] | Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001 |
[4] | Li JingBo, Liu Shu, Wen Bo, Gao Nan, Wang BingYuan. Clinical significance of Fibro Touch,ultrasound,and computed tomography in diagnosis of fatty liver disease: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(3): 459-462. doi: 10.3969/j.issn.1001-5256.2016.03.011 |
[5] | Cao HaiYang, Wu XiaoFeng, Lin DongDong. Research advances in fatty donor liver in liver transplantation[J]. Journal of Clinical Hepatology, 2015, 31(7): 1140-1143. doi: 10.3969/j.issn.1001-5256.2015.07.036 |
[6] | Zhang Yu, Cheng Jun. Hepatitis C virus related fatty liver[J]. Journal of Clinical Hepatology, 2015, 31(7): 1034-1037. doi: 10.3969/j.issn.1001-5256.2015.07.009 |
[7] | Tang ShaoShan, Zhao GuoJia, Wang YiJiao. Assessment of ultrasound elastography to grade hepatic steatosis in a rat model[J]. Journal of Clinical Hepatology, 2013, 29(4): 282-285. |
[8] | Dong Shu, Liu Ping, Sun MingYu. Role of “two-hit” in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(7): 551-555. |
[9] | Zhou ShuYun, Sun ZheYing. Therapeutic efficacy of polyunsaturated phosphatidylcholine on fatty liver disease[J]. Journal of Clinical Hepatology, 2010, 26(3): 286-287. |
[10] | Xiang GuoQing, Meng XiaoDan, Wang BingYuan. Prevalence of fatty liver among people with different occupation in Shenyang[J]. Journal of Clinical Hepatology, 2010, 26(3): 283-285. |
[11] | Qin YongJun, Sun JieSheng, Wang BingYuan, Liu PengLiang, Sun FuRong, Liu CuiXiang, Xie DaWei. The differences of the blood routine indexes in patients with fatty liver and non-fatty liver[J]. Journal of Clinical Hepatology, 2010, 26(2): 163-166. |
[12] | Xu YuWu, Liu YingZi, Fan JianGao, Yang Lin. Preliminary study on quantification of ultrasonographic classification of fatty liver [J]. Journal of Clinical Hepatology, 2010, 26(3): 267-268+280. |
[13] | Wan Hong, Li Ling, Tang YanPing. study on fatty liver prevalence in the government officers in Lanzhou area[J]. Journal of Clinical Hepatology, 2008, 24(4): 261-262. |
[15] | Hu DeYou. Ultrasonic monitoring of relationship between exercise and fatty liver[J]. Journal of Clinical Hepatology, 2004, 20(1): 34-35. |
[16] | Ding YanHua, He ShuMei, Wang XiaoWei, Xu MaoFeng, Niu JunQi. The clinical feature of 198 patients with fatty liver[J]. Journal of Clinical Hepatology, 2004, 20(5): 287-288. |